
Women who receive the prophylactic bivalent human papilloma virus (HPV) vaccine within 90 days of pregnancy are not at an increased risk for miscarriage, underscoring the safety of the vaccine. The proven safety of the bivalent HPV vaccine should quell the concerns of women and their health care practitioners.